This site is intended for healthcare professionals

Xenon Pharmaceuticals receives FDA feedback and plans to initiate XEN 496 phase III clinical trial for the treatment of KCNQ2-DEE before year-end.

Read time: 1 mins
Last updated:16th Mar 2021
Published:12th Oct 2020
Condition: KCNQ2 epileptic encephalopathy
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest